APTIVATE Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia.

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503244-14-00

Acronym

HM-FLTI-101

Enrollment

103

Registered

2023-06-12

Start date

2023-08-11

Completion date

2024-09-19

Last updated

2024-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory Acute Myeloid Leukemia (AML)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Poland, Spain, Sweden

None listed

Source: EU CTIS · Data processed: Feb 4, 2026